// App-Quantinova.ai

372 : Taselisib enhances the potency of ERBB inhibitors in biomarker-defined subsets of head and neck squamous carcinoma cell lines

Researchers

Presenter

  • Heidi M. Savage

Principal Investigators

  • Carol OBrien

  • Heather Moore

  • Mark R. Lackner

  • Robert Yauch

  • Jeffrey Settleman

  • Timothy R. Wilson

Medical Centers

  • Genentech, Inc., South San Francisico, CA

Locations

  • United States

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Squamous cell carcinoma

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Epidermal growth factor receptor

  • erb-b2 receptor tyrosine kinase 2

  • Erb-B2 Receptor Tyrosine Kinase 3

  • Fibroblast growth factor receptor 1

Drug/Treatment

  • Taselisib

  • Lapatinib

  • Erlotinib hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved